The official prescribing information should be consulted for treatment decisions.
The current U.S. Olumiant label was revised in June 2026.
U.S. indications
The current U.S. label includes:
- Moderately to severely active rheumatoid arthritis in adults after inadequate response to one or more TNF blockers
- COVID-19 in hospitalized adults requiring specified respiratory support
- Severe alopecia areata in adults
Dosage
Current U.S. dosing differs by indication:
- RA: 2 mg once daily
- COVID-19: 4 mg once daily for up to 14 days or hospital discharge
- Alopecia areata: 2 mg once daily, with escalation to 4 mg in specified circumstances
Contraindications
The current U.S. label lists no formal contraindications, but numerous warnings, precautions and treatment restrictions apply.
Major warnings
The boxed warning includes:
- Serious infections
- Mortality
- Malignancy
- Major adverse cardiovascular events
- Thrombosis
Other warnings
Additional warnings include:
- Hypersensitivity
- Gastrointestinal perforation
- Laboratory abnormalities
- Vaccination considerations
- Pregnancy-related risks
Official source
For healthcare professionals, use the current official label rather than relying solely on this summary.